These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37839266)

  • 1. Simultaneous quantification of nirmatrelvir/ritonavir in human serum by LC-HRMS.
    Zhao F; Xiang Z; Han J; Pan J; Qu Y; Fan K; Wu Z; Xu D; Yu Y; Shen Z; Su C
    J Pharm Biomed Anal; 2024 Jan; 237():115796. PubMed ID: 37839266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19.
    Martens-Lobenhoffer J; Böger CR; Kielstein J; Bode-Böger SM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1212():123510. PubMed ID: 36274268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC-MS/MS and its pharmacokinetic application in healthy Chinese volunteers.
    Liu C; Zhu M; Cao L; Boucetta H; Song M; Hang T; Lu Y
    Biomed Chromatogr; 2022 Nov; 36(11):e5456. PubMed ID: 35881032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Simple and Rapid LC-MS/MS Method for the Quantification of Nirmatrelvir/Ritonavir in Plasma of Patients with COVID-19.
    Zhu X; Li L; Dai B; Liu Z; Wang Z; Cui L; Gao S; Chen W; Tao X; Xu D
    Int J Anal Chem; 2024; 2024():6139928. PubMed ID: 38481558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous measurement of COVID-19 treatment drugs (nirmatrelvir and ritonavir) in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
    Zhou CJ; Liu YN; Wang A; Wu H; Xu RA; Zhang Q
    Heliyon; 2024 Jun; 10(11):e32187. PubMed ID: 38868075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
    Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
    Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
    Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
    Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the use of Paxlovid in clinical practice.
    McCarthy MW
    Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homogeneous liquid-liquid microextraction coupled with HPLC/DAD for determination of nirmatrelvir and ritonavir as COVID-19 combination therapy in human plasma.
    Abdallah IA; Hammad SF; Bedair A; Mansour FR
    BMC Chem; 2023 Nov; 17(1):166. PubMed ID: 38001530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [LC-MS/MS method for simultaneous quantification of lopinavir and ritonavir in human plasma].
    Yao YM; Sun JJ; Chen J; Liu XQ; Lu HZ; Zhang LJ
    Yao Xue Xue Bao; 2010 Feb; 45(2):279-82. PubMed ID: 21351441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy.
    Dong R; Huang Y; Ling X; Li L; Yu W; Jiang S
    Int J Antimicrob Agents; 2024 Jan; 63(1):106997. PubMed ID: 37848106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.
    Guyon J; Novion M; Fulda V; Ducint D; Molimard M; Couzi L; Kaminski H; Salvo F; Bouchet S
    J Am Soc Mass Spectrom; 2022 Oct; 33(10):1975-1981. PubMed ID: 36084269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
    Dawood AA
    Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
    Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S
    Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis.
    Chan PLS; Singh RSP; Cox DS; Shi H; Damle B; Nicholas T
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1897-1910. PubMed ID: 37803876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
    Lingscheid T; Kinzig M; Krüger A; Müller N; Bölke G; Tober-Lau P; Münn F; Kriedemann H; Witzenrath M; Sander LE; Sörgel F; Kurth F
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0122922. PubMed ID: 36286542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
    Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
    Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir.
    Caronia L; Xi R; Margolskee RF; Jiang P
    Biochem Biophys Res Commun; 2023 Nov; 682():138-140. PubMed ID: 37806252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19.
    Navitha Reddy G; Jogvanshi A; Naikwadi S; Sonti R
    Expert Rev Anti Infect Ther; 2023; 21(9):943-955. PubMed ID: 37525997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.